Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Abrocitinib on PK of Probe Drugs
NCT05067439Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abrocitinib in atopic dermatitis (AD), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time, Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time Corrected for Residual Concentrations and 1 more. Started Oct 2021; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05067439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067439.